Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial
BACKGROUND The purpose of this multicentre, multinational trial was to study whether rLH supplementation to recombinant FSH (rFSH) during the late follicular phase increased pregnancy rates. METHODS After down-regulation with nafarelin, 526 women were randomized on Day 1 of stimulation to use either...
Gespeichert in:
| Veröffentlicht in: | Human reproduction (Oxford) 2008-02, Vol.23 (2), p.427-434 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 434 |
|---|---|
| container_issue | 2 |
| container_start_page | 427 |
| container_title | Human reproduction (Oxford) |
| container_volume | 23 |
| creator | NyboeAndersen, A. Humaidan, P. Fried, G. Hausken, J. Antila, L. Bangsbøll, S. Rasmussen, P.E. Lindenberg, S. Bredkjaer, H. Ejdrup Meinertz, H. |
| description | BACKGROUND The purpose of this multicentre, multinational trial was to study whether rLH supplementation to recombinant FSH (rFSH) during the late follicular phase increased pregnancy rates. METHODS After down-regulation with nafarelin, 526 women were randomized on Day 1 of stimulation to use either rFSH (Gonal-F) alone (n = 261) or to continue after Day 6 of stimulation with both rFSH (Gonal-F) and rLH (Luveris) (n = 265) from Day 6. The starting dose of rFSH was 150–225 IU/day according to age below or above 35 years. RESULTS Ongoing pregnancy rate at week 10–12 was 28.7% after rFSH alone and 27.2% after rFSH + rLH. This showed no evidence of a difference. Administration of rLH significantly (P< 0.001) increased serum LH. Ongoing pregnancy rates in patients with low LH levels ( |
| doi_str_mv | 10.1093/humrep/dem317 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70210025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/humrep/dem317</oup_id><sourcerecordid>1420403061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-587849504d92621b4ad2ab0e87429acddf357155aed1c7276e1de5b44395f4243</originalsourceid><addsrcrecordid>eNqF0c1u1DAQAOAIgWhZOHJFFlIRh6a1HTtOjqWiXcpKICgS4mJ57Ql1ceJgOyvah-PZcMmqVFx68t-nmfFMUTwn-IDgtjq8mPoA46GBviLiQbFLWI1LWnH8sNjFtG5KQmqyUzyJ8RLjvG3qx8UOaTBlrBG7xe9PoH2_toMaElotUZzG0UEPQ1LJ-gElj8IdcfJ5icwU7PAdpQtAXb51yKiriHyHtB9S8M6BQX6jglUDisn2k5tDdT4gO6CNzQh1EJJ19vrv0wE6Qpklq3PeAPtoDD6OoJPd5ENQg_G9vQazfzdFygnc0-JRp1yEZ9t1UXw5eXt-vCxXH07fHR-tSs1JnUreiIa1HDPT0pqSNVOGqjWGRjDaKm1MV3FBOFdgiBZU1EAM8DVjVcs7Rlm1KF7NcXNlPyeISfY2anBODeCnKAWmBGPK74UU15SJtsnw5X_w0k8htzMbQtqK3Ux3UZQz0rkhMUAnx2B7Fa4kwfIGyHn8ch5_9i-2Qad1D-af3s47g70tUFEr1-XeahtvHcU4_55U2b2enZ_Ge3Nua7Qxwa9brMIPWYtKcLn8-k2-Of94drp8T-RZ9QdNwdsX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211934109</pqid></control><display><type>article</type><title>Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>NyboeAndersen, A. ; Humaidan, P. ; Fried, G. ; Hausken, J. ; Antila, L. ; Bangsbøll, S. ; Rasmussen, P.E. ; Lindenberg, S. ; Bredkjaer, H. Ejdrup ; Meinertz, H.</creator><creatorcontrib>NyboeAndersen, A. ; Humaidan, P. ; Fried, G. ; Hausken, J. ; Antila, L. ; Bangsbøll, S. ; Rasmussen, P.E. ; Lindenberg, S. ; Bredkjaer, H. Ejdrup ; Meinertz, H. ; Nordic LH study group ; The Nordic LH study group</creatorcontrib><description>BACKGROUND The purpose of this multicentre, multinational trial was to study whether rLH supplementation to recombinant FSH (rFSH) during the late follicular phase increased pregnancy rates. METHODS After down-regulation with nafarelin, 526 women were randomized on Day 1 of stimulation to use either rFSH (Gonal-F) alone (n = 261) or to continue after Day 6 of stimulation with both rFSH (Gonal-F) and rLH (Luveris) (n = 265) from Day 6. The starting dose of rFSH was 150–225 IU/day according to age below or above 35 years. RESULTS Ongoing pregnancy rate at week 10–12 was 28.7% after rFSH alone and 27.2% after rFSH + rLH. This showed no evidence of a difference. Administration of rLH significantly (P< 0.001) increased serum LH. Ongoing pregnancy rates in patients with low LH levels (<33 percentile) on Days 1 and 6 of stimulation showed no difference between the group treated with rFSH only (23.9% low Day 1 LH; 22.1% low Day 6 LH) versus rFSH + rLH (25.0% low Day 1 LH; 28.9% low Day 6 LH). CONCLUSIONS Supplementing rFSH with daily doses of 75–150 IU of rLH during the second half of the follicular phase showed no evidence of increasing the ongoing pregnancy rates in the general population. (ClinicalTrials.gov, trial number: KF02-035/03).</description><identifier>ISSN: 0268-1161</identifier><identifier>EISSN: 1460-2350</identifier><identifier>DOI: 10.1093/humrep/dem317</identifier><identifier>PMID: 18024487</identifier><identifier>CODEN: HUREEE</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Biological and medical sciences ; Drug Therapy, Combination ; Female ; Fertilization in Vitro ; Follicle Stimulating Hormone - therapeutic use ; Follicular Phase ; Gynecology. Andrology. Obstetrics ; Humans ; Luteinizing Hormone - blood ; Luteinizing Hormone - therapeutic use ; Medical sciences ; Ovulation Induction - methods ; Pregnancy ; Pregnancy Rate ; Recombinant Proteins - therapeutic use ; Treatment Failure</subject><ispartof>Human reproduction (Oxford), 2008-02, Vol.23 (2), p.427-434</ispartof><rights>The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008</rights><rights>2008 INIST-CNRS</rights><rights>The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-587849504d92621b4ad2ab0e87429acddf357155aed1c7276e1de5b44395f4243</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20072713$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18024487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NyboeAndersen, A.</creatorcontrib><creatorcontrib>Humaidan, P.</creatorcontrib><creatorcontrib>Fried, G.</creatorcontrib><creatorcontrib>Hausken, J.</creatorcontrib><creatorcontrib>Antila, L.</creatorcontrib><creatorcontrib>Bangsbøll, S.</creatorcontrib><creatorcontrib>Rasmussen, P.E.</creatorcontrib><creatorcontrib>Lindenberg, S.</creatorcontrib><creatorcontrib>Bredkjaer, H. Ejdrup</creatorcontrib><creatorcontrib>Meinertz, H.</creatorcontrib><creatorcontrib>Nordic LH study group</creatorcontrib><creatorcontrib>The Nordic LH study group</creatorcontrib><title>Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial</title><title>Human reproduction (Oxford)</title><addtitle>Hum Reprod</addtitle><description>BACKGROUND The purpose of this multicentre, multinational trial was to study whether rLH supplementation to recombinant FSH (rFSH) during the late follicular phase increased pregnancy rates. METHODS After down-regulation with nafarelin, 526 women were randomized on Day 1 of stimulation to use either rFSH (Gonal-F) alone (n = 261) or to continue after Day 6 of stimulation with both rFSH (Gonal-F) and rLH (Luveris) (n = 265) from Day 6. The starting dose of rFSH was 150–225 IU/day according to age below or above 35 years. RESULTS Ongoing pregnancy rate at week 10–12 was 28.7% after rFSH alone and 27.2% after rFSH + rLH. This showed no evidence of a difference. Administration of rLH significantly (P< 0.001) increased serum LH. Ongoing pregnancy rates in patients with low LH levels (<33 percentile) on Days 1 and 6 of stimulation showed no difference between the group treated with rFSH only (23.9% low Day 1 LH; 22.1% low Day 6 LH) versus rFSH + rLH (25.0% low Day 1 LH; 28.9% low Day 6 LH). CONCLUSIONS Supplementing rFSH with daily doses of 75–150 IU of rLH during the second half of the follicular phase showed no evidence of increasing the ongoing pregnancy rates in the general population. (ClinicalTrials.gov, trial number: KF02-035/03).</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fertilization in Vitro</subject><subject>Follicle Stimulating Hormone - therapeutic use</subject><subject>Follicular Phase</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Luteinizing Hormone - blood</subject><subject>Luteinizing Hormone - therapeutic use</subject><subject>Medical sciences</subject><subject>Ovulation Induction - methods</subject><subject>Pregnancy</subject><subject>Pregnancy Rate</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Treatment Failure</subject><issn>0268-1161</issn><issn>1460-2350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0c1u1DAQAOAIgWhZOHJFFlIRh6a1HTtOjqWiXcpKICgS4mJ57Ql1ceJgOyvah-PZcMmqVFx68t-nmfFMUTwn-IDgtjq8mPoA46GBviLiQbFLWI1LWnH8sNjFtG5KQmqyUzyJ8RLjvG3qx8UOaTBlrBG7xe9PoH2_toMaElotUZzG0UEPQ1LJ-gElj8IdcfJ5icwU7PAdpQtAXb51yKiriHyHtB9S8M6BQX6jglUDisn2k5tDdT4gO6CNzQh1EJJ19vrv0wE6Qpklq3PeAPtoDD6OoJPd5ENQg_G9vQazfzdFygnc0-JRp1yEZ9t1UXw5eXt-vCxXH07fHR-tSs1JnUreiIa1HDPT0pqSNVOGqjWGRjDaKm1MV3FBOFdgiBZU1EAM8DVjVcs7Rlm1KF7NcXNlPyeISfY2anBODeCnKAWmBGPK74UU15SJtsnw5X_w0k8htzMbQtqK3Ux3UZQz0rkhMUAnx2B7Fa4kwfIGyHn8ch5_9i-2Qad1D-af3s47g70tUFEr1-XeahtvHcU4_55U2b2enZ_Ge3Nua7Qxwa9brMIPWYtKcLn8-k2-Of94drp8T-RZ9QdNwdsX</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>NyboeAndersen, A.</creator><creator>Humaidan, P.</creator><creator>Fried, G.</creator><creator>Hausken, J.</creator><creator>Antila, L.</creator><creator>Bangsbøll, S.</creator><creator>Rasmussen, P.E.</creator><creator>Lindenberg, S.</creator><creator>Bredkjaer, H. Ejdrup</creator><creator>Meinertz, H.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7ST</scope><scope>7U6</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20080201</creationdate><title>Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial</title><author>NyboeAndersen, A. ; Humaidan, P. ; Fried, G. ; Hausken, J. ; Antila, L. ; Bangsbøll, S. ; Rasmussen, P.E. ; Lindenberg, S. ; Bredkjaer, H. Ejdrup ; Meinertz, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-587849504d92621b4ad2ab0e87429acddf357155aed1c7276e1de5b44395f4243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fertilization in Vitro</topic><topic>Follicle Stimulating Hormone - therapeutic use</topic><topic>Follicular Phase</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Luteinizing Hormone - blood</topic><topic>Luteinizing Hormone - therapeutic use</topic><topic>Medical sciences</topic><topic>Ovulation Induction - methods</topic><topic>Pregnancy</topic><topic>Pregnancy Rate</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NyboeAndersen, A.</creatorcontrib><creatorcontrib>Humaidan, P.</creatorcontrib><creatorcontrib>Fried, G.</creatorcontrib><creatorcontrib>Hausken, J.</creatorcontrib><creatorcontrib>Antila, L.</creatorcontrib><creatorcontrib>Bangsbøll, S.</creatorcontrib><creatorcontrib>Rasmussen, P.E.</creatorcontrib><creatorcontrib>Lindenberg, S.</creatorcontrib><creatorcontrib>Bredkjaer, H. Ejdrup</creatorcontrib><creatorcontrib>Meinertz, H.</creatorcontrib><creatorcontrib>Nordic LH study group</creatorcontrib><creatorcontrib>The Nordic LH study group</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Environment Abstracts</collection><collection>Sustainability Science Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Human reproduction (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NyboeAndersen, A.</au><au>Humaidan, P.</au><au>Fried, G.</au><au>Hausken, J.</au><au>Antila, L.</au><au>Bangsbøll, S.</au><au>Rasmussen, P.E.</au><au>Lindenberg, S.</au><au>Bredkjaer, H. Ejdrup</au><au>Meinertz, H.</au><aucorp>Nordic LH study group</aucorp><aucorp>The Nordic LH study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial</atitle><jtitle>Human reproduction (Oxford)</jtitle><addtitle>Hum Reprod</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>23</volume><issue>2</issue><spage>427</spage><epage>434</epage><pages>427-434</pages><issn>0268-1161</issn><eissn>1460-2350</eissn><coden>HUREEE</coden><abstract>BACKGROUND The purpose of this multicentre, multinational trial was to study whether rLH supplementation to recombinant FSH (rFSH) during the late follicular phase increased pregnancy rates. METHODS After down-regulation with nafarelin, 526 women were randomized on Day 1 of stimulation to use either rFSH (Gonal-F) alone (n = 261) or to continue after Day 6 of stimulation with both rFSH (Gonal-F) and rLH (Luveris) (n = 265) from Day 6. The starting dose of rFSH was 150–225 IU/day according to age below or above 35 years. RESULTS Ongoing pregnancy rate at week 10–12 was 28.7% after rFSH alone and 27.2% after rFSH + rLH. This showed no evidence of a difference. Administration of rLH significantly (P< 0.001) increased serum LH. Ongoing pregnancy rates in patients with low LH levels (<33 percentile) on Days 1 and 6 of stimulation showed no difference between the group treated with rFSH only (23.9% low Day 1 LH; 22.1% low Day 6 LH) versus rFSH + rLH (25.0% low Day 1 LH; 28.9% low Day 6 LH). CONCLUSIONS Supplementing rFSH with daily doses of 75–150 IU of rLH during the second half of the follicular phase showed no evidence of increasing the ongoing pregnancy rates in the general population. (ClinicalTrials.gov, trial number: KF02-035/03).</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>18024487</pmid><doi>10.1093/humrep/dem317</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-1161 |
| ispartof | Human reproduction (Oxford), 2008-02, Vol.23 (2), p.427-434 |
| issn | 0268-1161 1460-2350 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70210025 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Biological and medical sciences Drug Therapy, Combination Female Fertilization in Vitro Follicle Stimulating Hormone - therapeutic use Follicular Phase Gynecology. Andrology. Obstetrics Humans Luteinizing Hormone - blood Luteinizing Hormone - therapeutic use Medical sciences Ovulation Induction - methods Pregnancy Pregnancy Rate Recombinant Proteins - therapeutic use Treatment Failure |
| title | Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A05%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20LH%20supplementation%20to%20recombinant%20FSH%20during%20the%20final%20days%20of%20controlled%20ovarian%20stimulation%20for%20in%20vitro%20fertilization.%20A%20multicentre,%20prospective,%20randomized,%20controlled%20trial&rft.jtitle=Human%20reproduction%20(Oxford)&rft.au=NyboeAndersen,%20A.&rft.aucorp=Nordic%20LH%20study%20group&rft.date=2008-02-01&rft.volume=23&rft.issue=2&rft.spage=427&rft.epage=434&rft.pages=427-434&rft.issn=0268-1161&rft.eissn=1460-2350&rft.coden=HUREEE&rft_id=info:doi/10.1093/humrep/dem317&rft_dat=%3Cproquest_cross%3E1420403061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=211934109&rft_id=info:pmid/18024487&rft_oup_id=10.1093/humrep/dem317&rfr_iscdi=true |